142 related articles for article (PubMed ID: 17342312)
1. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Kanzaki M; Kakinuma H; Kumazawa T; Inoue T; Saito M; Narita S; Yuasa T; Tsuchiya N; Habuchi T
Oncol Rep; 2007 Apr; 17(4):761-7. PubMed ID: 17342312
[TBL] [Abstract][Full Text] [Related]
2. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
Zhang Z; Stanfield J; Frenkel E; Kabbani W; Hsieh JT
Urology; 2007 Aug; 70(2):396-401. PubMed ID: 17826527
[TBL] [Abstract][Full Text] [Related]
3. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
[TBL] [Abstract][Full Text] [Related]
5. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Sasaki Y; Negishi H; Idogawa M; Suzuki H; Mita H; Toyota M; Shinomura Y; Imai K; Tokino T
Mol Cancer Ther; 2008 Apr; 7(4):779-87. PubMed ID: 18413792
[TBL] [Abstract][Full Text] [Related]
7. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
[TBL] [Abstract][Full Text] [Related]
8. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
Karam JA; Fan J; Stanfield J; Richer E; Benaim EA; Frenkel E; Antich P; Sagalowsky AI; Mason RP; Hsieh JT
Int J Cancer; 2007 Apr; 120(8):1795-802. PubMed ID: 17230511
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
Kasman L; Lu P; Voelkel-Johnson C
Cancer Gene Ther; 2007 Mar; 14(3):327-34. PubMed ID: 17186014
[TBL] [Abstract][Full Text] [Related]
10. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Nelson SD; Dry SM; Li Y; Russell TA; Singh AS; Chmielowski B; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(11):1063-1069. PubMed ID: 28426279
[TBL] [Abstract][Full Text] [Related]
11. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
Rayburn ER; Wang W; Zhang Z; Li M; Zhang R; Wang H
Prostate; 2006 Nov; 66(15):1653-63. PubMed ID: 16927305
[TBL] [Abstract][Full Text] [Related]
12. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
[TBL] [Abstract][Full Text] [Related]
14. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
15. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Son DS; Wilson AJ; Parl AK; Khabele D
Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo].
Xu DB; Wang YL; Yue Y; Wu SC; Ding H
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477
[TBL] [Abstract][Full Text] [Related]
18. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Aribi A; Gery S; Lee DH; Thoennissen NH; Thoennissen GB; Alvarez R; Ho Q; Lee K; Doan NB; Chan KT; Toh M; Said JW; Koeffler HP
Int J Cancer; 2013 Jun; 132(12):2730-7. PubMed ID: 23165325
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
20. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
